Antony Mersiades, MD, FRACP, MBBS, University of Sydney & NHMRC Clinical Trials Centre & Northern Beaches Cancer Service, Sydney, Australia, discusses findings from the Phase II/III CannabisCINV study (ACTRN12616001036404) of an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting. Patients who have previously received anti-emetics received a 1:1 THC/CBD extract over six days. Despite the poor accrual, the primary endpoint was reached, where overall efficacy was markedly improved in patients receiving THC/CBD cannabis extract. Some patients had dizziness from the cannabis extract, but no serious adverse events were reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
